Enanta制药 ENTA 深 沪
等待开盘 10-16 09:30:00 美东时间
11.6601
+0.700
+6.39%
华盛通- 最 高11.69
- 今 开11.06
- 成交量 24.86万股
- 最 低 11.01
- 昨 收 10.96
- 总市值 2.49亿
- 52周最高 15.34
- 市盈率 静 --
- 换手率 1.16%
- 52周最低 4.09
- 委 比 90.82%
- 总股本 2137.66万
- 历史最高 127.77
- 量 比 0.68
- 振 幅 6.20%
- 历史最低 4.09
- 每 手 1
- 风险率 2.08%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Enanta Pharmaceuticals to Showcase RSV Drug Data at IDWeek 2025, Highlighting Two Oral Once-Daily Treatments
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for
10-07 19:14
美股大行评级 | 潜在涨幅162.68%！Ocular Therapeutix获JMP证券升目标价至29美元，维持"跑赢大市"评级
今日重点评级关注：JMP证券：维持Ocular Therapeutix"跑赢大市"评级，目标价从20美元升至29美元；汇丰银行：上调Banco BBVA Argentina评级至"买入"，目标价从21美元下调至17美元
10-02 15:08
Enanta Pharmaceuticals Announces Public Stock Offering
Enanta Pharmaceuticals ( ($ENTA) ) has issued an update. On September 30, 2025,...
10-02 05:06
Is The Nike Turnaround Story In Play?
Nike delivers a mixed but encouraging quarter, and a turnaround narrative is starting to take shape.
10-02 00:11
美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
Enanta pharmaceuticals prices $65M common stock offering
Enanta Pharmaceuticals (NASDAQ:ENTA) has priced its public offering of 6.5M common shares at $10.00 per share for gross proceeds of $65.0M. The company has granted the underwriters a 30-day option to...
10-01 12:50
美股牛股 | Enanta制药飙涨92%！新药获FDA快速通道资格；加密货币股Bakkt大涨42%
Enanta制药单日飙涨92%！旗下新药获FDA快速通道资格；比特币快速反弹至11.4万美元上方，加密货币股Bakkt隔夜大涨42%>>
09-30 17:15
Biggest stock movers Monday: GSK, MLTX, and more
Stock futures were higher Monday morning while Treasury yields slipped as investors awaited September’s upcoming nonfarm payrolls report, hoping for clarity on U.S. labor market health, while also wei...
09-29 17:17
Enanta Pharmaceuticals shares are trading higher after the company announced it will present topline results from its Phase 2b study of Zelicapavir for RSV in high-risk adults on Monday.
Enanta Pharmaceuticals shares are trading higher after the company announced it...
09-27 04:03
Roche deal to buy 89bio boosts MASH space
Shares of companies focused on developing drugs for a liver condition called metabolic dysfunction-associated steatohepatitis (MASH) traded higher on Thursday after Roche (OTCQX:RHHBY) (OTCQX:RHHBF) a...
09-18 22:41
